Memantine
- Atc Codes:N06DX01
- CAS Codes:19982-08-2#41100-52-1
- PHARMGKB ID:19982-08-2#41100-52-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Inhibits
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Axura, Ebixa; Belgium: Ebixa; Bulgaria: Ebixa; Cyprus: Ebixa; Czech Republic: Axura, Ebixa; Denmark: Axura, Ebixa; Estonia: Axura, Ebixa; Finland: Ebixa; France: Ebixa; Germany: Axura, Ebixa, Memantin; Greece: Ebixa; Hungary: Axura, Ebixa; Ireland: Axura, Ebixa, Memantine; Italy: Ebixa; Latvia: Axura, Ebixa; Lithuania: Axura, Ebixa; Luxembourg: Axura, Ebixa; Malta: Ebixa; Netherlands: Axura, Ebixa; Poland: Axura, Ebixa; Portugal: Axura, Ebixa; Romania: Axura, Ebixa; Slovakia: Axura, Ebixa; Slovenia: Axura, Ebixa; Spain: Axura, Ebixa; Sweden: Axura, Ebixa; UK: Ebixa.
North America
Canada: Ebixa, Memantine; USA: Memantine, Namenda.
Latin America
Argentina: Akatinol, Carrier, Conexine, Ebixa, Fentina, Lucidex, Merital, Neuroplus, Prilben, Pronervon, Tonibral; Brazil: Alois, Ebix; Mexico: Akatinol, Ebixa, Eutebrol.
Drug combinations
Chemistry
Memantine: C~12~H~21~N. Mw: 179.30. 3,5-Dimethyl-1-adamantanamine. CAS-19982-08-2.
Memantine Hydrochloride: C~12~H~21~N HCl. Mw: 215.76. (1) Tricyclo[3.3.1.13,7]decan-1-amine, 3,5-dimethyl-, hydrochloride; (2) 3,5-Dimethyltricyclo[3.3.1.13,7]decan-1-amine hydrochloride; (3) 3,5-Dimethyl-1-adamantanamine hydrochloride. CAS-41100-52-1 (2003).
Pharmacologic Category
Other Anti-Dementia Drugs; N-Methyl-D-Aspartate Receptor Antagonist. (ATC-Code: N06DX01).
Mechanism of action
Low- to moderate-affinity, noncompetitive NMDA receptor antagonist. Binds preferentially to NMDA receptor-operated cation channels. May act by blocking actions of glutamate, mediated in part by NMDA receptors.
Therapeutic use
Palliative treatment of moderate to severe dementia of the Alzheimer’s type (Alzheimer’s disease).
Pregnancy and lactiation implications
Teratogenic effects not observed in animal studies. There are as yet no studies in pregnant women. Use caution if administered while breast-feeding.
Unlabeled use
Treatment of mild-to-moderate vascular dementia. Mild cognitive impairment.
Contraindications
Hypersensitivity to memantine or any component of the formulation.
Warnings and precautions
Use with caution in severe hepatic or renal impairment, or in history of seizure disorder (might increase risk of seizures). Clearance significantly reduced by alkaline urine (use caution with medications, dietary changes, or patient conditions which may alter urine pH).